In terms of safety, SGLT2 inhibitors are generally well tolerated, with a low intrinsic risk of hypoglycemia when used as monotherapy because of their insulin-independent mechanism of action [36]. This evidence concerns the gene SLC5A2 and Hypoglycemia.